CELC

investors.com/news/technologycelcuity-stock-three-drug-regimen-breast-cancer/?src=A00220
#CELC
The article says Celcuity's phase 3 breast-cancer regimen produced strong results: the triple combo of gedatolisib, palbociclib, and fulvestrant cut the risk of progression or death by 76%, and the doublet cut it by 67% versus fulvestrant
alone. clinicaltrialsarena +1

It also says median progression-free survival was 9.3 months for the triple therapy and 7.4 months for the doublet, compared with 2.0 months for the control arm, and that Celcuity planned an FDA filing in Q4 2025.

$CELC INTERNAL NEWS ** THIS STOCK WILL BE COLLAPSED SOON DUE TO FAIL OF THE PRODUCT IN PHASE II .

$CELC NO VOLUMES ！ DO BODY BUY ! HOLD IS LOSING POCKETS MONEY.

$CELC THIS IS GHOST STOCK.
FRAUD STOCK .LOSING $MILLION OF MONEY COMPANY

$CELC FROM INTERNAL NEWS :THIS IS LOSING ALOT OF MONEY COMPANY.
THE RESEARCH BURNED MONEY AND GET NOTHING.

$CELC TIME TO SELL AND GET PROFIT NOW.
HOLDING WILL LOSING POCKETS MONEY.

$CELC NO VOLUMES... MEANS NO BODY WANT TO BUY.
LOSING MONEY COMPANY.
SELL IS STRONGLY RECOMMENDED...

$CELC THIS IS LOSING $MILLION MONEY COMPANY.
CANCER RESEARCH NOT SUITABLE FOR THERAPY.
BURN ALOT OF $$$$ ALREADY.

$CELC THIS IS LOSING $M MONEY COMPANY
SAME AS $CARA . SELL NOW GET YOUR PROFIT..

$CELC THIS IS LOSING $M MONEY COMPANY
SAME AS $ CARA . SELL NOW GET YOUR PROFIT..